SEC Form 4 · accession 0001209191-18-063791
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Judith V Klimovsky
Director
Period of report
Dec 20, 2018
Accepted (ET)
Dec 20, 2018 · 9:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.36 | Dec 20, 2018 | A | 50,000 | A | — | Dec 19, 2028 | Common Stock | 50,000 | 50,000 | D |
| Stock Option (right to buy)F2 | $3.36 | Dec 20, 2018 | A | 12,500 | A | — | Dec 19, 2028 | Common Stock | 12,500 | 12,500 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 36 equal monthly installments over a three-year period beginning from December 20, 2018.
- F2The stock option vests and becomes exercisable in equal monthly installments until the date of the Company's 2019 annual meeting of stockholders.